218 related articles for article (PubMed ID: 35655709)
1. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.
Baleeiro RB; Bouwens CJ; Liu P; Di Gioia C; Dunmall LSC; Nagano A; Gangeswaran R; Chelala C; Kocher HM; Lemoine NR; Wang Y
Oncoimmunology; 2022; 11(1):2080329. PubMed ID: 35655709
[TBL] [Abstract][Full Text] [Related]
2. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
3. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
4. MHC class II expression in pancreatic tumors: a link to intratumoral inflammation.
Gaida MM; Welsch T; Herpel E; Tschaharganeh DF; Fischer L; Schirmacher P; Hänsch GM; Bergmann F
Virchows Arch; 2012 Jan; 460(1):47-60. PubMed ID: 22120497
[TBL] [Abstract][Full Text] [Related]
5. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
6. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC.
Wang J; Zhang T; Li P; Gai J; Chen S; Espinoza G; Kung HC; Zhang R; Fujiwara K; Fu J; Yu J; Zheng L
Cancer Lett; 2023 Oct; 573():216366. PubMed ID: 37640197
[TBL] [Abstract][Full Text] [Related]
7. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
8. Tumor cells fail to present MHC-II-restricted epitopes derived from oncogenes to CD4+ T cells.
Brightman SE; Naradikian MS; Thota RR; Becker A; Montero L; Bahmanof M; Premlal ALR; Greenbaum JA; Peters B; Cohen EE; Miller AM; Schoenberger SP
JCI Insight; 2023 Jan; 8(2):. PubMed ID: 36512410
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
10. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
[TBL] [Abstract][Full Text] [Related]
12. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
[TBL] [Abstract][Full Text] [Related]
13. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
15. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
18. Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer.
Sang W; Zhou Y; Chen H; Yu C; Dai L; Liu Z; Chen L; Fang Y; Ma P; Wu X; Kong H; Liao W; Jiang H; Qian J; Wang D; Liu YH
Cancer Discov; 2024 Feb; 14(2):326-347. PubMed ID: 37824278
[TBL] [Abstract][Full Text] [Related]
19. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
[TBL] [Abstract][Full Text] [Related]
20. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
